IC
PRAX icon

Ikarian Capital’s Praxis Precision Medicines PRAX Stock Holding History

Ikarian Capital’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$301K Buy
+900
New +$285K 0.03% 134
2024
Q3 		– Sell
-4,225
Closed -$17.5M – 167
2024
Q2 		$17.5M Buy
+4,225
New +$200K 3.04% 9

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Ikarian Capital's PRAX Position: Q2 2026 in Review

Ikarian Capital increased its Praxis Precision Medicines (PRAX) stake by 1.8% in Q2 2026, buying an estimated $399K and bringing the position to 72,842 shares worth $24.4M. The position accounts for 2.63% of the portfolio, ranked #9.

Ikarian Capital first reported a position in PRAX in Q4 2020 and has held it in 11 quarters since. The position peaked at $25.5M in Q4 2025. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Ikarian Capital held 72,842 shares of Praxis Precision Medicines worth $24.4M as of Q2 2026.
  • Ikarian Capital bought 1,261 Praxis Precision Medicines shares in Q2 2026, an estimated $399K.
  • Praxis Precision Medicines made up 2.63% of Ikarian Capital's portfolio in Q2 2026, its #9 holding.
  • Ikarian Capital first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 11 quarters since.
  • Ikarian Capital's Praxis Precision Medicines position peaked at $25.5M in Q4 2025.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.